Medication non‐adherence patterns and profiles for patients with incident myocardial infarction: Observations from a large multi‐morbid US population

Abstract

AbstractBackgroundConsistent adherence levels to multiple long‐term medications for patients with cardiovascular conditions are typically advocated in the range of 50% or higher, although very likely to be much lower in some populations. We investigated this issue in a large cohort covering a broad age and geographical spectrum, with a wide range of socio‐economic disability status.MethodsThe patients were drawn from three different health plans with a varied mix of socio‐economic/disability levels. Adherence patterns were examined on a monthly basis for up to 12 months past the index date for myocardial infarction (MI) using longitudinal analyses of group‐based trajectory modelling. Each of the non‐adherent patterns was profiled from comorbid history, demographic and health plan factors using main effect logistic regression modelling. Four medication classes were examined for MI: betablockers, statin, ACE inhibitors and anti‐platelets.ResultsThe participant population for the MI/non‐MI cohorts was 1,987,605 (MI cohort: mean age 62 years, 45.9% female; non‐MI cohort: mean age 45 years, 55.3% females). Cohorts characterized by medication non‐adherence dominated the majority of MI population with values ranging from 74% to 82%. There were four types of consistent non‐adherence patterns as a function of time for each medication class: fast decline, slow decline, occasional users and early gap followed by increased adherence. The characteristics of non‐adherence profiles eligible for improvement included patients with a prior history of hypertension, diabetes mellitus and stroke as co‐morbidities, and Medicare plan.ConclusionsWe found consistent patterns of intermediate non‐adherence for each of four drug classes for MI cohorts in the order of 56% who are eligible for interventions aimed at improving cardiovascular medication adherence levels. These insights may help improve cardiovascular medication adherence using large medication non‐adherence improvement programs.